Literature DB >> 1975379

Prevalence of antibody to heterologous circumsporozoite protein of Plasmodium vivax in Thailand.

R A Wirtz1, R Rosenberg, J Sattabongkot, H K Webster.   

Abstract

The distribution in Thailand of antibody to a recently discovered variant of circumsporozoite proteins of Plasmodium vivax was determined by enzyme-linked immunosorbent assay (ELISA). The ELISA capture antigens were a synthetic peptide of the principal variant sequence ANGAGNQPG and a candidate P vivax vaccine that contained the predominant repeat sequence GDRAA/DGQPA. Serological evidence of recent inoculation with the variant was found throughout Thailand and in migrants from Cambodia, Malaysia, and Burma. IgG antibody to the two P vivax circumsporozoite proteins was detected in 217 of 804 test sera (27%). Within the regions studied the proportion of positive sera specific for the variant epitope ranged from 28% to 66%. A vaccine against the predominant repeat domain may rapidly select for the variant, which already appears to be widespread within Thailand.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975379     DOI: 10.1016/0140-6736(90)93393-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea.

Authors:  J W Park; S H Moon; J S Yeom; K J Lim; M J Sohn; W C Jung; Y J Cho; K W Jeon; W Ju; C S Ki; M D Oh; K Choe
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

2.  Plasmodium vivax blood-stage dynamics.

Authors:  F Ellis McKenzie; Geoffrey M Jeffery; William E Collins
Journal:  J Parasitol       Date:  2002-06       Impact factor: 1.276

Review 3.  What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?

Authors:  Carolina López; Yoelis Yepes-Pérez; Natalia Hincapié-Escobar; Diana Díaz-Arévalo; Manuel A Patarroyo
Journal:  Front Immunol       Date:  2017-02-13       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.